OGEN (Oragenics Inc.) רווח נקי למניה (EPS TTM)

Oragenics, Inc. (OGEN) management is actively attracting investment to commercialize drugs for pulmonary infections. The fundamental TTM net income per share metric on the GURU.Markets chart confirms asset movement, where the -2.21 level reflects the current magnitude. Stable FCF is supported by patents for oral medications, while growth potential is based on unique intranasal delivery of neurosteroids for CNS injuries.

This indicator is calculated by dividing the aggregate net income over the last four quarters by the total number of shares outstanding. The metric determines the investor's actual equity return, reflecting the efficiency of capital generation. For Oragenics, Inc. (OGEN), this calculation confirms the monetization of its unique intranasal delivery method for neuroprotectors. Inelastic demand from the military and clinics provides potential for earnings growth. By analyzing the rolling earnings per share (EPS) figure, one can assess the sustainability of this fundamental momentum.